Loading
companiesCompany
US WorldMeds
US WorldMeds is a private Louisville company that took over the engineered T-cell therapies Tecelra and lete-cel from Adaptimmune in 2025 and sells eflornithine (Iwilfin) for maintenance in high-risk neuroblastoma. Whether a small private firm can sustain T-cell manufacturing for a rare sarcoma is the open question.
Also called: USWM, LLCUS WorldMedsUSWM
Overview
US WorldMeds, a private company based in Louisville, Kentucky, took over the cell therapies Tecelra and lete-cel from Adaptimmune in 2025 and markets eflornithine, sold as Iwilfin, for neuroblastoma. It acquired Adaptimmune's assets afamitresgene autoleucel and letetresgene autoleucel in August 2025, with a biologics licence application for lete-cel committed by the end of 2026, and Iwilfin was approved in December 2023 for maintenance in high-risk neuroblastoma. OnCo links it to sarcomas and paediatric neuroblastoma, to all three drug records, and to bottlenecks on rare and paediatric cancers without markets and the lack of incentive to repurpose cheap drugs. Whether a small private company can sustain engineered T-cell manufacturing for a rare sarcoma is the open question. Each product has its own page.
Headquarters
Louisville, KY, US
Scorecard
All companies#126of 1244 companies, score 44
- approved products +12
- phase 1/2 +1
- targets +4
- modalities +4
- regions +1
- 24-month regulatory events +8
- registry trials +14
2 approved, 0 in phase 3, 1 earlier, 2 targets, 48 registry studies. Formula on the scorecards page.
Type
Website
ApprovedTCR-T (MAGE-A4)
Afamitresgene autoleucel · Tecelra
Afamitresgene autoleucel was the first engineered T-cell receptor therapy approved for a solid tumour, synovial sarcoma.
Phase 2TCR-T (NY-ESO-1)
Letetresgene autoleucel is a second engineered T-cell receptor therapy for sarcoma, targeting NY-ESO-1 in synovial sarcoma and myxoid/round cell liposarcoma; a BLA is expected by the end of 2026.
ApprovedSmall-molecule ornithine decarboxylase inhibitor
Eflornithine (DFMO) · Iwilfin
Eflornithine (DFMO) is an old sleeping-sickness drug repurposed as the first oral maintenance therapy for high-risk neuroblastoma, approved in December 2023 to reduce relapse after immunotherapy.
Similar pages
- IdeaExtending sarcoma TCR-T beyond HLA-A*02
Shares Letetresgene autoleucel, Afamitresgene autoleucel, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- TrialNMTRC003/003B (DFMO maintenance)
Shares Eflornithine (DFMO), High-risk neuroblastoma, No incentive to repurpose cheap drugs, Neuroblastoma (paediatric).
- TechnologyTandem autologous transplant
Shares High-risk neuroblastoma, Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- IdeaPay a prize for rare cancer drugs instead of hoping for a market
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- TrialIGNYTE-ESO
Shares Letetresgene autoleucel, Sarcomas (soft tissue, bone, GIST).
- TermMYCN amplification
Shares Eflornithine (DFMO), High-risk neuroblastoma, Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- IdeaOpen-source drug discovery to clinical proof of concept for neglected cancers
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- CompanyY-mAbs Therapeutics
Shares High-risk neuroblastoma, Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
cancers
fronts
drugs
ApprovedTCR-T (MAGE-A4)
Afamitresgene autoleucel · Tecelra
ApprovedSmall-molecule ornithine decarboxylase inhibitor
Eflornithine (DFMO) · Iwilfin
Phase 2TCR-T (NY-ESO-1)